Posts for Ticker ‘XOMA’

XOMA’s Hijack Financing On News (XOMA)

Money Stack ImageXOMA Ltd. (NASDAQ: XOMA) has seen shares on a tear yesterday and then again this morning. It was late yesterday that the company said it would also be entitled to royalties from its partner’s approval for CIMZIA after an approval indication for rheumatoid arthritis.  And it was just this morning that the company announced a collaboration with Zymeworks for an antibody research program.  Now, the company announced that it is raising about $10 million, via a share sale.
Read More »

Posted on: May 15, 2009 – 8:46 am in Biotech, Drug companies, Secondary Offering,

Biotech Business Daily (AMAG, CEGE, IMCL, XOMA, TRCA)

AMAG Pharmaceuticals (NASDAQ: AMAG) has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI) beginning May 19, 2008. AMAG shares up $1.26 at $39.85. The 52-week range is $38.16 to $72.95.

Cell Genesys (NASDAQ: CEGE) offered 7.1 shares for $30 million in gross proceeds to a single institutional investor at $4.22 per share to finance product development and general corporate purposes. Shares are down 6% to $42.12. The 52-week is $30.34 to $49.18.

Imclone Systems Inc. (NASDAQ: IMCL) is down almost 5% after a downgrade by Morgan Stanley, citing belief that Erbitux will fail to reach expectations. Shares are trading at $42.31 in mid-day trading. The 52-week range is $30.34 to $49.18.

XOMA Ltd. (NASDAQ: XOMA) down over 8% after reporting larger than expected first quarter losses. They showed a loss of $14.2 million and revenues of $12.1 million, failing to hit estimates by Thomson of $16.4 million. Shares trading at $2.12. The 52-week range is $1.96 to $4.39.

Tercica Inc. (NASDAQ: TRCA) up almost 7% today in anticipation of positive first quarter earnings to be announced after market close. Shares trading at $4.77on a 52-week range of $4.30 to $8.11.

Rachel Lopez
May 12, 2008

Posted on: May 12, 2008 – 1:21 pm in Biotech, , , , ,

Xoma Gets A Boost

Biopharmaceutical company Xoma (XOMA) is having its luck day. After its stock traded down as low as $2.24, its shares are up almost 20% today on news that it bacterial cell expression technology to Pfizer to Pfzier (PFE). The deal comes with a $30 million up-front payment.

While that may not seem like much, XOMA lost $7.5 million on revenue of $14.1 million in the last quarter.

The stock still appears expensive, with a market cap of $370 million.

Maybe the royalties on the Pfizer deal, if there end up being any, will help justify the company’s valuation.

Douglas A. McIntyre

Posted on: August 28, 2007 – 8:38 am in Biotech, ,